“As I said at the beginning, we see the second half of the year as stronger. That momentum is carried into 2027, and we continue to see double-digit growth by the end of the decade.”

In context

“nt, opportunities for further geographic expansion, and the large and growing global burden of heart disease. To your question around recovery, as already mentioned by Joe, we do expect this to take some time, but we absolutely expect that our performance in the back half will be stronger than the first, and we see gradual improvements in performance back to double-digit growth over the coming quarters. Thank you again. Joaquin Duato Thank you, Tim. It's also important to put this into context. Heart recovery is one of 28 platforms of more than a billion dollars that we have within Johnson & Johnson. While we see this situation that Tim described as temporary and fully addressable, I have to be clear, it does not affect in any shape or fashion our growth trajectory as we have described. As I said at the beginning, we see the second half of the year as stronger. That momentum is carried into 2027, and we continue to see double-digit growth by the end of the decade. Ryan Kurz Thank you, Jayson. We have time for one last question. Operator Thank you. Our final question today is coming from Mike Nolkovich from TD Cowen. Your line is now live. Mike Nolkovich Hi. Thank you so much for the question. My question is on TREMFYA. In GI, TREMFYA seems to have an edge over SKYRIZI, yet SKYRIZI is holding its own. My question is, to what do you attribute SKYRIZI's ability to hold share? Thank you. Jennifer Taubert Good morning. Thanks so much for the question. I'm thrilled to have the opportunity to talk about TREMFYA. TREMFYA's sales for the quarter were $2 billion, our first $2 billion quarter and over 70% growth which we're really proud of. I mentioned before that we continue to see growth and share gains in psoriatic disease. I've got to tell you, th”